Our study reveals that serum leucine-rich α-2 glycoprotein 1 (LRG-1) is an independent prognostic marker for breast cancer-specific survival. This finding might translate into novel diagnostic approaches especially as the analysis of serum samples in patients with cancer are more readily available, cost-effective and can be easily implemented into routine clinical diagnostics.